Lut Lynen

Medicine & Life Sciences

1. HIV 100%
2. Cambodia 99%
3. Tuberculosis 79%
4. Visceral Leishmaniasis 59%
5. Ethiopia 56%
6. Rifampin 45%
7. Guinea 33%
8. Retrospective Studies 31%
9. Viral Load 30%
10. Therapeutics 30%
11. Cohort Studies 29%
12. Zimbabwe 28%
13. CD4 Lymphocyte Count 26%
14. Hepatitis C 25%
15. Treatment Failure 24%
16. Ebola Hemorrhagic Fever 23%
17. Multidrug-Resistant Tuberculosis 22%
18. Coinfection 19%
19. Lost to Follow-Up 19%
20. HIV Infections 18%
21. Immune Reconstitution Inflammatory Syndrome 17%
22. Stavudine 17%
23. Lesotho 16%
24. Guidelines 16%
25. Belgium 16%
26. Health Facilities 14%
27. Highly Active Antiretroviral Therapy 14%
28. Prednisone 13%
29. Hepacivirus 12%
30. Myanmar 11%
31. Afghanistan 10%
32. Pharmaceutical Preparations 10%
33. Mortality 10%
34. Zidovudine 10%
35. Isoniazid 10%
36. Acquired Immunodeficiency Syndrome 10%
37. Confidence Intervals 10%
38. Africa South of the Sahara 10%
39. Eastern Africa 8%
40. Leishmaniasis 7%
41. Recurrence 7%
42. Microscopy 7%
43. Infection 7%
44. Antimony Sodium Gluconate 7%
45. Placebos 7%
46. Clinical Trials 7%
47. 2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine 7%
48. Cross-Sectional Studies 7%
49. Public Health 7%